USA Archives

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Progress of COPD drug boosted by debt financing of up to $150M

Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […]

October 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Gene activity could help identify risk of kidney cancer spreading

Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet (KI) in Sweden in a preclinical study published in Nature Communications. “This could potentially […]

October 17, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

More positive news announced for Verona’s COPD treatment

Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […]

October 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Way to transform Cas-9 protein into spherical nuclear acid developed

A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […]

October 17, 2022 - 4 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

PerkinElmer’s Horizon Discovery: the lowdown on base editing

PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and development. Horizon’s portfolio is focused on research reagents; screening and cell line engineering services; bioproduction cell lines; reference standards and base editing. Horizon’s base editing platform, Pin-point is a gene editing method with the ability to effect multiple single base edits […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

More News! 14 Oct 2022

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Oct 2022

Cytel signs agreement with two Scandinavian medicinal product companies

U.S.-based Cytel Inc. has entered into an agreement to acquire Scandinavian companies SDS Life Sciences AB and SDS MedeQ AB. Cytel says the move will add new talent to the company’s strategic consulting group and bring additional capabilities for the development of drugs and medical devices. It says sponsors will also have easier access to […]

October 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 14 Oct 2022

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Plan launched to improve diversity of clinical trials

Help to improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age and ethnicity has been revealed. Medidata, a Dassault Systèmes company, has launched the intelligent trials diversity module. The new module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites […]

October 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment

The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has invested in Samsara Therapeutics Inc. Samsara Therapeutics is a biotech company focusing on discovering and developing therapeutics to restore autophagy – the process by which cells recycle damaged or dysfunctional components. Samsara is developing several novel, […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, are collaborating to improve manufacturing and analytic procedures to develop personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Empyrean Neuroscience launches with $22M to target CNS disorders

Progress of COPD drug boosted by debt financing of up to $150M

Gene activity could help identify risk of kidney cancer spreading

More positive news announced for Verona’s COPD treatment

Way to transform Cas-9 protein into spherical nuclear acid developed

PerkinElmer’s Horizon Discovery: the lowdown on base editing

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

Cytel signs agreement with two Scandinavian medicinal product companies

A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation

Plan launched to improve diversity of clinical trials

CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!